Madrigal Pharmaceuticals, Inc. (MDGL)
Madrigal Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in West Conshohocken, PA, US. The stock last traded at $533.76, down 1.83% on the session, giving a market capitalisation of $12.33B. On trailing twelve-month figures it carries a trailing P/E of -41.41, a net margin of -25.3%. Its beta of -1.00 implies it has historically moved less than the broad market.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals, Inc. is most often compared with the following Healthcare names: